Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Pharma & Biotech
Pharma & Biotech
LifeNet Health acquires Tissue Testing Technologies to scale biopreservation in regenerative medicine
LifeNet Health has announced the acquisition of Tissue Testing Technologies LLC (T3), a South Carolina–based biotechnology company specializing in advanced biopreservation. The deal expands LifeNet Health’s capabilities in organ and tissue preservation by integrating proprietary vitrification and warming technologies developed by Tissue Testing Technologies. The transaction is positioned to enhance clinical transplantation success rates, support
Pharma & Biotech
Is Zegen-15 the breakthrough diabetic foot ulcer therapy insurers will finally cover?
Zegenex, a Pittsburgh-based biotechnology company focused on regenerative wound care, has secured a $215,000 social-impact investment from the Richard King Mellon Foundation to accelerate formulation and preclinical development of Zegen-15, a first-in-class small-molecule cream targeting chronic wounds, including diabetic foot ulcers. The funding positions Zegenex to begin clinical trials by the end of 2026 and
Pharma & Biotech
Spiderwort Biotechnologies’ cellulose scaffolds show promise in spinal cord repair
Spiderwort’s spinal cord scaffold earns scientific validation as its dermal filler enters human trials Spiderwort Biotechnologies Inc. has reported two key developments in its cellulose-based regenerative platform, signaling a step forward in both neurorepair and aesthetic medicine. A peer-reviewed study published in Scientific Reports confirms that the company’s plant-derived scaffolds promote neural tissue repair and
Pharma & Biotech
Is DOXA the multi-mechanism small molecule NewcelX needs for narcolepsy and ALS?
NewcelX Ltd. has announced the publication of its international DOXA compound patent in China, further securing intellectual property protection for its cross-domain pipeline in neurology and metabolic diseases. The patent application covers a new class of small molecules derived from quinazoline, benzothiazine, and benzoxazine scaffolds. These compounds are designed to modulate orexin signaling, neuroinflammation, and
Medical Devices & Diagnostics
Inside Xtant Medical’s Strata launch: What sets it apart from legacy bone grafts
Xtant Medical Holdings, Inc. has launched its next-generation synthetic bone graft, nanOss Strata, in the United States. The graft, built from hydroxycarbonapatite (HCA), is designed to enhance bioactivity and integration in orthopedic and spinal surgeries. This launch follows the company’s strategic exit from non-core spinal implant assets, signaling a renewed focus on its biologics portfolio.